FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Randomized, Double-Blind, Plac.-Controlled Clinical Study to Compare the Efficacy of FP-101 60mg b.i.d. vs. Placebo for the Treatment of Moderate-to-Severe Hot Flashes in Peri- and Post-menopausal Women Over a Period of 1-Week.

This Phase II proof of concept study is designed to assess the safety and efficacy of FP-101 (60mg b.i.d.), an extended-release oral tablet product, compared to a matching placebo in the treatment of moderate-to-severe hot flashes in peri- and post-menopausal women over a period of 1-week.

Study Overview

• Status: Completed
• Conditions: Vasomotor Symptoms; Menopause
• Intervention / Treatment: Drug: FP-101

Detailed Description

This randomized, double-blind, parallel-group, placebo-controlled, clinical trial is designed to compare patient-reported changes in Vasomotor Symptoms (VMS) for FP-101 vs. placebo in peri- and post-menopausal women. The study will be run as a fully decentralized clinical trial (DCT), by use of components such as electronic Consent (eConsent), mobile/tele health visits, electronic Patient Reported Outcomes (ePROs), and direct-to-participant shipping of the (investigational medicinal product (IMP). The DCT approach to this study will rely on a digital platform through which subjects can consent, enroll, and interact with the PI and study staff. Proper regulatory framework and technology use will ensure compliance with Good Clinical Practice (GCP), ethics & legal/regulatory requirements.

Healthy peri- and post-menopausal women (>45 years of age) suffering from VMS will be recruited if they have >=7- 8 moderate to severe hot flushes per day at baseline. After meeting all eligibility criteria subjects will be enrolled and start a 1-week run-in period to identify/eliminate placebo responders, as well as to exclude subjects who have difficulty completing the eDiary. Any Adverse Events (AEs) during the run-in period will serve as baseline for the safety assessments at the end of the treatment period.

Eligible subjects will undergo a tele health baseline visit during which the criteria for inclusion in the treatment period will be confirmed. Over a 1-week treatment period, subjects will complete a daily electronic Diary (eDiary) to record any AEs and the frequency and severity of hot flashes during the past 12hr interval. In the morning, subjects will record the number of awakenings during the past night and the number of night sweats.

The PI will conduct an end-of-study visit with each of the subjects randomized to the study medications to review safety and efficacy data, complete a Patient Global Improvement Scale, and clarify any open issues with the subjects.

------------------------------

• Study Type: Interventional
• Enrollment (Actual): 105
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Helmut H Albrecht, MD; Phone Number: 973-454 9859; Email: Helmut.Albrecht@Lumanity.com
• Study Contact Backup: Name: Giovanni Ciavarra, PhD; Phone Number: 110 973-889 1600; Email: Giovanni.Ciavarra@Lumanity.com

Study Locations

• United States
  • California
    • Lomita, California, United States, 90717
      • Torrance Clinical Research Institute
    • Long Beach, California, United States, 90806
      • Long Beach Clinical Trial Services
    • West Covina, California, United States, 91790
      • Provideré Research Inc.
  • Florida
    • Hialeah, Florida, United States, 33013
      • Inpatient Research Clinic
    • Miami Lakes, Florida, United States, 33016
      • The Angel Medical Research Corporation
    • New Port Richey, Florida, United States, 34652
      • Suncoast Clinical Research - Pasco County
  • North Carolina
    • Cary, North Carolina, United States, 27518
      • Cary Medical Group
    • Raleigh, North Carolina, United States, 27609
      • Raleigh Medical Group
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19114
      • Clinical Research of Philadelphia
  • South Carolina
    • North Charleston, South Carolina, United States, 29405
      • Coastal Carolina Research Center
  • Texas
    • San Antonio, Texas, United States, 78209
      • ICON Early Phase Services
    • San Antonio, Texas, United States, 78258
      • Discovery Clinical Trials - Stone Oak

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 46 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Peri- and Post-Menopausal female subjects (>45 yrs) experiencing a min of 7-8 moderate to severe hot flashes per day
• Able/willing to provide informed consent.
• Able/willing to complete all study procedures and visits.
• Able/willing to not use any over-the-counter (OTC) cough & cold medications that contain the IMP active during the study.

Exclusion Criteria:

• Subject exhibits positive home pregnancy test at screening or any time during study
• Subject currently taking any form of Hormone Therapy (HT), including local estrogen therapies
• Subject currently taking tamoxifen, other selective estrogen receptor modulators, or other hormone deprivation therapy.
• Subject with history of serotonergic syndrome
• Subject is currently taking monoamine oxidase inhibitors (MAOIs) (or for 2 weeks after stopping the MAOI drug), antidepressants, thioridazine, pimozide, cannabidiol, opioids, antipsychotic agents, antiretroviral agents, quinidine, quinine, or other medications for VMS such as Brisdelle® (paroxetine mesylate), clonidine and gabapentin.
• Subject is currently taking a dietary/herbal supplement(s) to manage VMS, such as soy isoflavones or black cohosh.
• Subject has uncontrolled diabetes, a history of hypertension & is not on a stable dose of antihypertensive medications for at least 30 days prior to screening.
• Subject has clinically unstable cardiac disease, including atrial fibrillation, symptomatic brady- or tachy-arrhythmias, congestive heart failure (NYHA class II, III, and IV), or symptomatic atherosclerotic cardiovascular disease (coronary artery disease, carotid artery disease or peripheral artery disease) or history of myocardial infarction or stroke within 2 years of enrolment in the study.
• Subject reports medical history suggestive of impaired liver/kidney function or, in the PI's opinion, exhibits liver/kidney function impairment to the extent that the subject should not participate in the study.
• Subject has biliary tract disease, adrenal cortical insufficiency, or any other medical condition that, in the PI's opinion (and after discussion with the medical monitor), is considered inadequately treated and precludes entry into the study.
• Subject has thyroid disease, unless subject is clinically stable with normal thyroid indices and is on maintenance thyroid medication (e.g., levothyroxine or liothyronine) for ≥6 months prior to screening.
• Subject has a history of, or is currently presenting with, substance use disorder as defined by the 5th Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Subject has a history of psychiatric disorders, including a lifetime history of major depressive disorder, bipolar disorder, panic disorder, generalized anxiety, psychotic disorders, suicidality or suicidal ideation, or post-traumatic stress disorder.
• Subject is currently participating in another clinical trial
• Subjects who were determined to be placebo responders or non-compliant during the 1-week run-in period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Active Treatment (FP-101); White to off-white extended-release, round tablets containing FP-101.	Drug: FP-101; daily oral tablet administration (b.i.d.)
Placebo Comparator: Matching placebo; White to off-white round tablets without the active ingredient but otherwise matching in size and appearance.	Drug: FP-101; daily oral tablet administration (b.i.d.)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the frequency (average daily number) of moderate-to-severe hot flashes.	Subjects use a digital platform to record hot flash frequency in a daily eDiary.	Recorded every 12 hrs over a 1-week treatment period.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in the severity (average daily rating) of moderate-to-severe hot flashes.	Subjects use digital platform to record hot flash severity (3-point scale) in a daily eDiary.	Recorded every 12 hrs over a 1-week treatment period.
Change in nighttime awakenings (average daily number) with or without night sweats.	Subjects use daily eDiary to record nighttime awakenings & night sweats frequency.	Recorded every morning over a 1-week treatment period.
Evaluate the clinical meaningfulness of VMS changes after 1-week of treatment.	Completing validated Patient Global Improvement Scale (7-point) with PI.	After 1 week of treatment at the end-of-study visit.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Any Adverse Events and Concomitant Medications	Subjects will use daily eDiary to record any AEs and concomitant medications	Recorded as needed/every 12 hrs over a 1-week treatment period.

Collaborators and Investigators

• Sponsor: Fervent Pharmaceuticals
• Collaborators: ICON plc
• Investigators: Study Director: Helmut H Albrecht, MD, Lumanity

Study record dates

Study Major Dates

• Study Start (Actual): March 24, 2021
• Primary Completion (Actual): April 5, 2023
• Study Completion (Actual): July 31, 2023

Study Registration Dates

• First Submitted: March 28, 2022
• First Submitted That Met QC Criteria: March 28, 2022
• First Posted (Actual): April 5, 2022

Study Record Updates

• Last Update Posted (Actual): October 26, 2023
• Last Update Submitted That Met QC Criteria: October 24, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Other Study ID Numbers: 2021-FERV

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plans to share data with other researchers

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No